Targeting BCL-2 regulated apoptosis in cancer
KJ Campbell, SWG Tait - Open biology, 2018 - royalsocietypublishing.org
The ability of a cell to undergo mitochondrial apoptosis is governed by pro-and anti-
apoptotic members of the BCL-2 protein family. The equilibrium of pro-versus anti-apoptotic …
apoptotic members of the BCL-2 protein family. The equilibrium of pro-versus anti-apoptotic …
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies
ARD Delbridge, S Grabow, A Strasser… - Nature Reviews Cancer, 2016 - nature.com
The'hallmarks of cancer'are generally accepted as a set of genetic and epigenetic
alterations that a normal cell must accrue to transform into a fully malignant cancer. It follows …
alterations that a normal cell must accrue to transform into a fully malignant cancer. It follows …
Patient-derived xenografts undergo mouse-specific tumor evolution
Patient-derived xenografts (PDXs) have become a prominent cancer model system, as they
are presumed to faithfully represent the genomic features of primary tumors. Here we …
are presumed to faithfully represent the genomic features of primary tumors. Here we …
BH3-mimetic drugs: blazing the trail for new cancer medicines
Defects in apoptotic cell death can promote cancer and impair responses of malignant cells
to anti-cancer therapy. Pro-survival BCL-2 proteins prevent apoptosis by keeping the cell …
to anti-cancer therapy. Pro-survival BCL-2 proteins prevent apoptosis by keeping the cell …
[HTML][HTML] Broad targeting of resistance to apoptosis in cancer
Apoptosis or programmed cell death is natural way of removing aged cells from the body.
Most of the anti-cancer therapies trigger apoptosis induction and related cell death networks …
Most of the anti-cancer therapies trigger apoptosis induction and related cell death networks …
Clinical review: navitoclax as a pro-apoptotic and anti-fibrotic agent
NN Mohamad Anuar, NS Nor Hisam, SL Liew… - Frontiers in …, 2020 - frontiersin.org
B-cell lymphoma 2 (BCL-2) family proteins primarily work as a programmed cell death
regulator, whereby multiple interactions between them determine cell survival. This explains …
regulator, whereby multiple interactions between them determine cell survival. This explains …
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
JD Leverson, DC Phillips, MJ Mitten… - Science translational …, 2015 - science.org
The BCL-2/BCL-XL/BCL-W inhibitor ABT-263 (navitoclax) has shown promising clinical
activity in lymphoid malignancies such as chronic lymphocytic leukemia. However, its …
activity in lymphoid malignancies such as chronic lymphocytic leukemia. However, its …
Patient-derived xenograft (PDX) models in basic and translational breast cancer research
LE Dobrolecki, SD Airhart, DG Alferez… - Cancer and Metastasis …, 2016 - Springer
Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly
supplanting long-established traditional cell lines as preferred models for conducting basic …
supplanting long-established traditional cell lines as preferred models for conducting basic …
RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers
Individuals who have mutations in the breast-cancer-susceptibility gene BRCA1 (hereafter
referred to as BRCA1-mutation carriers) frequently undergo prophylactic mastectomy to …
referred to as BRCA1-mutation carriers) frequently undergo prophylactic mastectomy to …
Patient-derived xenograft models of breast cancer and their predictive power
Despite advances in the treatment of patients with early and metastatic breast cancer,
mortality remains high due to intrinsic or acquired resistance to therapy. Increased …
mortality remains high due to intrinsic or acquired resistance to therapy. Increased …